Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT02484404 trial: what clinicians have said so far
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
- NCT02484404 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02484404 (durvalumab plus olaparib; durvalumab plus cediranib; durvalumab plus olaparib plus cediranib in advanced solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02484404 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Colorectal Neoplasms; Breast Neoplasms
- Interventions
- Olaparib; Cediranib; Durvalumab
- Arms
- P1 Durvalumab+C · Experimental
- P1 Durvalumab+O · Experimental
- P1 Durvalumab+O+C · Experimental
- P2 Durvalumab+C · Experimental
- P2 Durvalumab+O · Experimental
- P2 Durvalumab+O+C · Experimental
- Enrollment
- 268
- Primary outcomes
- Ph II Determine overall response rate of Durvalumab-O and Durvalumab-C in patients with recurrent ovarian cancer
- Ph I Determine the recommended phase II dose (RP2D) and the safety of doublet therapies of Durvalumab/olaparib (Durvalumab-O) and Durvalumab/cediranib (Durvalumab-C) in patients with advanced solid tumors
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jun 29, 2015
- Primary completion
- Oct 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02484404 · updated Nov 10, 2026
Publications
linked from the registry- Fialkoff G, Takahashi N, Sharkia I, Gutin J, Hermoni N, Nirula M, Kumar R, Pongor L, Nichols S, Sciuto L, Parmar K, Desai P, Suresh P, Abel M, El Meskini R, Maoz M, Rottenberg Y, Nevo S, Nechushtan H, Peretz T, Roame D, Hubert A, Cohen JE, Salah A, Temper M, Grinshpun A, Weaver-Ohler Z, Rajan A, Figg WD Sr, Zick A, Sadeh R, Friedman N, Thomas A. Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer. J Clin Invest. 2026 Oct 1;136(19):e202151. doi: 10.1172/JCI202151. eCollection 2026 Oct 1. PubMed 42820295
- Santiago-Sanchez G, Rosato F, Fabian KP, Padget MR, Lee JM, Karzai F, Schlom J, Gulley JL, Hamilton DH, Lee JK, Pruitt MR, Bayliffe A, Su Z, Moisan J, Katragadda M, Hodge JW. PARP inhibition combined with a T-cell receptor beta chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression. J Immunother Cancer. 2026 Jul 1;14(7):e014518. doi: 10.1136/jitc-2025-014518. PubMed 42386344
- Li C, Madan RA, Lee MJ, Lee S, Sato N, Rastogi S, Shrestha R, Aragon-Ching JB, Goswami M, Donahue RN, Cordes LM, Baj A, Seo CCY, Terrigino NT, Bright JR, Hennigan ST, King IM, Trostel SY, Fenimore JM, Liu Y, Calzone KA, Schlom J, Gulley JL, Dahut WL, Figg WD, Sowalsky AG, Lee JM, Karzai F. Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2026 Mar 25;14(3):e014365. doi: 10.1136/jitc-2025-014365. PubMed 41881502
- Fujii T, Cimino-Mathews A, Lipkowitz S, Lee MJ, Nair J, Solarz BB, Zimmer A, Redd B, Levy EB, Rastogi S, Sato N, McCoy A, Steinberg SM, Lee JM. A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation. Cancer Med. 2025 Dec;14(23):e71220. doi: 10.1002/cam4.71220. PubMed 41360639
- Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses. J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3. PubMed 31345267
- Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marte J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2. PubMed 30514390